Bristol-Myers Squibb Co- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Bristol-Myers Squibb Co 公司

公司簡介

公司代碼BMY

公司名稱Bristol-Myers Squibb Co

上市日期Jul 05, 1929

成立日期1933

CEODr. Christopher S. (Chris) Boerner, Ph.D.

員工數量34100

證券類型Ordinary Share

年結日Jul 05

公司地址Route 206 And Province Line Road

城市PRINCETON

上市交易所NYSE Consolidated

國家United States of America

郵編08543

電話16092524621

網址https://www.bms.com/in

公司代碼BMY

上市日期Jul 05, 1929

成立日期1933

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Ms. Sandra Leung

Executive Vice President, General Counsel, Member of the Leadership Team

448.10K

+6.18%

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer, Chief Operating Officer

104.62K

+1.95%

Mr. Samit Hirawat, M.D.

Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team

63.93K

+2.94%

Dr. Julia A. Haller, M.D.

Independent Director

13.61K

--

Mr. Phil Holzer

Senior Vice President, Controller

11.76K

-5.62%

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

6.65K

+1.16K%

Ms. Karin Shanahan

Executive Vice President, Global Product Development & Supply, Member of the Leadership Team

5.33K

+65.41%

Ms. Cari Gallman

Executive Vice President, Corporate Affairs, Member of the Leadership Team

5.01K

+137.97%

Mr. Robert Plenge, M.D., Ph.D.

Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team

--

Mr. Peter J. (Pete) Arduini

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Ms. Sandra Leung

Executive Vice President, General Counsel, Member of the Leadership Team

448.10K

+6.18%

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer, Chief Operating Officer

104.62K

+1.95%

Mr. Samit Hirawat, M.D.

Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team

63.93K

+2.94%

Dr. Julia A. Haller, M.D.

Independent Director

13.61K

--

Mr. Phil Holzer

Senior Vice President, Controller

11.76K

-5.62%

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

6.65K

+1.16K%

收入明細

單位: USD更新時間: 3月5日週三

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Eliquis

13.33B

27.60%

Opdivo

9.30B

19.26%

Revlimid

5.77B

11.95%

Orencia

3.68B

7.62%

Pomalyst/Imnovid

3.54B

7.33%

Other

12.66B

26.21%

地區USD

名稱

營收

佔比

United States

34.10B

70.61%

International

13.19B

27.32%

other

996.00M

2.06%

業務

地區

業務USD

名稱

營收

佔比

Eliquis

13.33B

27.60%

Opdivo

9.30B

19.26%

Revlimid

5.77B

11.95%

Orencia

3.68B

7.62%

Pomalyst/Imnovid

3.54B

7.33%

Other

12.66B

26.21%

股東統計

更新時間: 2月21日週五

持股股東

股東類型

持股股東

股東統計

佔比

The Vanguard Group, Inc.

9.31%

BlackRock Institutional Trust Company, N.A.

4.78%

State Street Global Advisors (US)

4.68%

JP Morgan Asset Management

3.10%

Charles Schwab Investment Management, Inc.

2.97%

Other

75.13%

持股股東

股東統計

佔比

The Vanguard Group, Inc.

9.31%

BlackRock Institutional Trust Company, N.A.

4.78%

State Street Global Advisors (US)

4.68%

JP Morgan Asset Management

3.10%

Charles Schwab Investment Management, Inc.

2.97%

Other

75.13%

股東類型

股東統計

佔比

Investment Advisor

36.81%

Investment Advisor/Hedge Fund

32.60%

Research Firm

2.76%

Pension Fund

2.50%

Bank and Trust

2.25%

Sovereign Wealth Fund

1.85%

Hedge Fund

1.70%

Holding Company

0.23%

Insurance Company

0.16%

Other

19.10%

機構持股

更新時間: 1月19日週日

報告期間

機構數

持股數

持股佔比

持股變動

2025Q1

4136

1.64B

81.10%

+16.36M

2024Q4

4261

1.64B

81.14%

+17.04M

2024Q3

4116

1.59B

78.69%

-22.72M

2024Q2

4105

1.58B

78.35%

-83.11M

2024Q1

4118

1.64B

80.97%

+13.32M

2023Q4

4115

1.60B

78.83%

-46.38M

2023Q3

4042

1.62B

77.83%

-55.49M

2023Q2

4082

1.65B

78.77%

-34.93M

2023Q1

4110

1.65B

78.74%

-34.09M

2022Q4

4105

1.65B

77.92%

-72.60M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

189.01M

9.31%

+1.40M

+0.74%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

97.01M

4.78%

-7.45M

-7.13%

Dec 31, 2024

State Street Global Advisors (US)

95.14M

4.68%

+2.24M

+2.42%

Dec 31, 2024

JP Morgan Asset Management

63.09M

3.1%

+12.35M

+24.34%

Dec 31, 2024

Charles Schwab Investment Management, Inc.

60.30M

2.97%

-729.92K

-1.19%

Dec 31, 2024

Capital International Investors

45.86M

2.26%

+3.21M

+7.54%

Dec 31, 2024

Geode Capital Management, L.L.C.

44.39M

2.18%

+1.18M

+2.74%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

35.17M

1.73%

+2.58M

+7.91%

Dec 31, 2024

Columbia Threadneedle Investments (US)

28.49M

1.4%

+12.26M

+75.54%

Dec 31, 2024

Fidelity Management & Research Company LLC

27.55M

1.35%

-9.07M

-24.77%

Dec 31, 2024

持股ETF

更新時間: 12 小時前

機構名稱

佔比

First Trust NASDAQ Pharmaceuticals ETF

8.03%

Invesco S&P Ultra Dividend Revenue ETF

6.78%

NYLI Healthy Hearts ETF

4.96%

iShares U.S. Pharmaceuticals ETF

4.8%

Invesco Pharmaceuticals ETF

4.79%

VanEck Morningstar Wide Moat Value ETF

4.58%

VanEck Pharmaceutical ETF

4.37%

Schwab U.S. Dividend Equity ETF

4.3%

Cullen Enhanced Equity Income ETF

3.79%

SPDR S&P Pharmaceuticals ETF

3.67%

First Trust NASDAQ Pharmaceuticals ETF

佔比8.03%

Invesco S&P Ultra Dividend Revenue ETF

佔比6.78%

NYLI Healthy Hearts ETF

佔比4.96%

iShares U.S. Pharmaceuticals ETF

佔比4.8%

Invesco Pharmaceuticals ETF

佔比4.79%

VanEck Morningstar Wide Moat Value ETF

佔比4.58%

VanEck Pharmaceutical ETF

佔比4.37%

Schwab U.S. Dividend Equity ETF

佔比4.3%

Cullen Enhanced Equity Income ETF

佔比3.79%

SPDR S&P Pharmaceuticals ETF

佔比3.67%

分紅派息

近5年累計派現 22.71B 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

Dec 11, 2024

BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option

Jan 03, 2025

Feb 03, 2025

Jan 03, 2025

Sep 10, 2024

BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option

Oct 04, 2024

Nov 01, 2024

Oct 04, 2024

Jun 18, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option

Jul 05, 2024

Aug 01, 2024

Jul 05, 2024

Mar 01, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option

Apr 05, 2024

May 01, 2024

Apr 04, 2024

Dec 06, 2023

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option

Jan 05, 2024

Feb 01, 2024

Jan 04, 2024

Sep 20, 2023

BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023

Oct 06, 2023

Nov 01, 2023

Oct 05, 2023

Jun 14, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option

Jul 07, 2023

Aug 01, 2023

Jul 06, 2023

Mar 03, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023

Apr 10, 2023

May 01, 2023

Apr 06, 2023

Dec 08, 2022

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023

Jan 06, 2023

Feb 01, 2023

Jan 05, 2023

Sep 14, 2022

BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022

Oct 07, 2022

Nov 01, 2022

Oct 06, 2022

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Bristol-Myers Squibb Co

59.820USD

Bristol-Myers Squibb Co

59.820

概覽

公司